The glucagon-like peptide-1 receptor agonist liraglutide is used to treat diabetes. A hallmark of liraglutide is the glucose-dependent facilitation of insulin secretion from pancreatic ␤-cells. In ␤-cells, the glycolytic enzyme glucokinase plays a pivotal role as a glucose sensor. However, the role of glucokinase in the glucose-dependent action of liraglutide remains unknown. We first examined the effects of liraglutide on glucokinase haploinsufficient (Gck ϩ/Ϫ ) mice. Single administration of liraglutide significantly improved glucose tolerance in Gck ϩ/Ϫ mice without increase of insulin secretion. We also assessed the effects of liraglutide on the survival rates, metabolic parameters, and histology of liver or pancreas of ␤-cell-specific glucokinase-deficient (Gck Ϫ/Ϫ ) newborn mice.
T he incretin glucagon-like peptide-1 (GLP-1) facilitates glucose-stimulated insulin release and contributes to plasma glucose homeostasis (1, 2) . GLP-1 receptor (GLP1R) agonists and dipeptidyl pepdidase-4 (DPP-4) inhibitors have been widely used for the treatment of type 2 diabetes (3). GLP1R agonists and DPP-4 inhibitors have also exhibited protective effects on ␤-cell apoptosis and other extrapancreatic tissues, such as the liver (4) .
Clinical studies have demonstrated that liraglutide, a long-acting GLP1R agonist, significantly improves glycemic control in type 2 diabetes patients (5-12). The major advantages of liraglutide for the treatment of diabetic patients, compared with other therapies, such as insulin or sulfonylurea, are a reduction in body weight and fewer episodes of hypoglycemia (13) . Liraglutide exerts an acute effect on pancreatic ␤-cell insulin release in response to glucose predominantly in the presence of elevated blood glucose levels, thereby preventing excessive insulin secretion in normoglycemic states. GLP1R activation has also been suggested to reduce glucagon secretion, reducing hypoglycemia (14, 15) . Liraglutide has also exhibited protective effects on pancreatic ␤-cells in rodent models (16, 17) . Moreover, GLP1R activation may reduce hepatic gluconeogenesis (4, 18) . However, the mechanisms underlying the glucose concentration-dependent facilitation of insulin secretion by liraglutide remain unclear.
Glucokinase, a member of the hexokinase family, is the main glucose sensor in ␤-cells (19) . Glucose-stimulated insulin secretion (GSIS) from pancreatic ␤-cells depends critically on glucokinase activity, and inactivating mutations cause either maturity onset diabetes of the young 2 or permanent neonatal diabetes (20) . Whether glucokinase is involved in the potentiation of insulin secretion by GLP1R agonists is uncertain. The expression of glucokinase in ␤-cells is critical for the maintenance of glycemic control (21) . We previously reported the characteristics of ␤-cell-specific glucokinase-deficient (Gck Ϫ/Ϫ ) mice, in which the neuron and ␤-cell-specific exon was disrupted (22) . Mice that were heterozygous for ␤-cell glucokinase (Gck ϩ/Ϫ ) exhibited impaired insulin secretion and manifested mild hyperglycemia, whereas mice that were homozygous for ␤-cell glucokinase (Gck Ϫ/Ϫ ) exhibited severe hyperglycemia and died within 1 wk after birth as a result of defective insulin secretion in response to glucose (22) . In this study, we used Gck Ϫ/Ϫ neonatal mice to evaluate the role of ␤-cell glucokinase in the actions of liraglutide and the effects on the survival rate, metabolic parameters, and histology of the endocrine pancreas and liver.
Materials and Methods

Animals and animal care
We backcrossed Gck ϩ/Ϫ mice with C57Bl/6J mice more than 10 times. Both the adult wild-type (WT) and Gck ϩ/Ϫ mice were fed standard chow (MF; Oriental Yeast, Tokyo, Japan). To generate the Gck Ϫ/Ϫ mice, we crossed Gck ϩ/Ϫ mice with each other. The neonatal WT, Gck ϩ/Ϫ , and Gck Ϫ/Ϫ mice were weaned normally, with most of the pups being preweaning period at 15 d after birth.
All the experiments were conducted on male littermates. All the animal procedures were performed in accordance with the institutional animal care guidelines and the guidelines of the Animal Care Committee of the Yokohama-City University. The animal housing rooms were maintained at a constant room temperature (25 C) and on a 12-h light (0700 h)/12-h dark (1900 h) cycle.
Drugs
Liraglutide, a long-acting human insulin analog (insulin detemir), and intermediateacting human insulin [neutral protamine Hagedorn (NPH)] in premanufactured sc injection pens were obtained from Novo Nordisk (Bagsvaerd, Denmark) and stored at 4 C until use. Saline solution was used as the vehicle control. For single administration experiments, the animals received either the vehicle or liraglutide (0.3 mg/kg ip) before oral glucose loading (1.5 mg/g) or insulin injection (0.75 mU/g). The ganglionic blocker chlorisondamine (CS) chloride (Sigma, St. Louis, MO) (3 mg/kg) and methyl atropine (Atr) (0.5 mg/kg; Sigma), a peripherally acting muscarinic blocker, were administered ip before the liraglutide injections. 
Measurement of biochemical parameters and cytokines
The plasma glucose levels, blood insulin levels, triglyceride (TG) content in the liver, and glycogen content in the liver were determined using a Glutest Neo Super (Sanwa Chemical Co., Tokyo, Japan), insulin kit (Morinaga, Tokyo, Japan), Determiner-L TG II kit, and Determiner-GL-E kit (Wako Pure Chemical Industries, Osaka, Japan), respectively. The plasma alanine aminotransferase (ALT), free fatty acid (FFA), total cholesterol (TChol), low-density lipoprotein cholesterol, and TG levels were assayed using enzymatic methods (Wako Pure Chemical Industries).
Histological analysis
Liver sections were prepared and stained using hematoxylin (Wako Pure Chemical Industries) according to the manufacturer's instructions. More than 10 pancreatic tissue sections from each animal were analyzed after fixation and paraffin embedding. The sections were immunostained with antibodies to insulin (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) and glucagon (Abcam, Cambridge, MA). Biotinylated secondary antibodies, a VECTASTAIN elite ABC kit, and a 3,3Ј-diaminobenzidine substrate kit (Vector Laboratories, Burlingame, CA) were used to examine sections using bright-field microscopy to determine the ␤-cell mass, and Alexa Fluor 488-and 555-conjugated secondary antibodies (Invitrogen, Carlsbad, CA) were used for fluorescence microscopy. All the images were acquired using a BZ-9000 microscope (Keyence, Osaka, Japan) or Carl Zeiss LSM 510 confocal laser-scanning microscope (Zeiss, Oberkochen, Germany). The proportion of the area of pancreatic tissue occupied by ␤-cells was calculated using BIOREVO software (Keyence), as described previously (23) . Briefly, after staining a pancreatic section with insulin antibody, the insulin-positive area relative to the area of the entire pancreatic tissue was calculated for more than five sections per mouse.
Statistical analyses
All the data were reported as the mean Ϯ SE and were analyzed using the Student's t test or ANOVA. Differences were considered significant if the P value was less than 0.05 (*).
Results
Single administration of liraglutide significantly improved glucose tolerance in both WT and Gck
We previously demonstrated that Gck ϩ/Ϫ islets exhibited the potentiation of GSIS via exendin-4, another GLP-1R agonist, at high glucose concentrations (23) . To confirm the effects of liraglutide on Gck ϩ/Ϫ mice, liraglutide (0.3 mg/kg) was injected ip 30 min before an oral glucose tolerance test (GTT) or an insulin tolerance test (ITT). Liraglutide significantly improved glucose tolerance in both WT and Gck ϩ/Ϫ mice (Fig. 1A) . The GSIS at 15 min after glucose loading was increased by liraglutide in WT mice but not in Gck ϩ/Ϫ mice (Fig. 1B) . Liraglutide did not affect insulin sensitivity after an insulin injection in both WT and Gck ϩ/Ϫ mice (Fig. 1C) of the autonomic nervous system (24) . The effects of autonomic nerve blockade on the action of liraglutide were evaluated by the ip administration of a ganglionic blocker, CS, or a peripheral muscarinic blocker, methyl Atr. Neither Atr nor CS affected the glucose-lowering effects of liraglutide in either WT or Gck ϩ/Ϫ mice ( Fig. 2A) , although the insulin secretion at 15 min after glucose administration was reduced by both Atr and CS (Fig. 2B) . (Fig. 3B ) and reduced the blood glucose levels in Gck Ϫ/Ϫ mice but not in the WT or Gck ϩ/Ϫ mice (Fig. 3C) . To exclude the possibility that the dose of liraglutide was insufficient to achieve an improvement, we injected the pups with a double dose of liraglutide. The double dose of liraglutide also did not improve the survival rate in Gck Ϫ/Ϫ mice (data not shown). We also assessed the effects of insulin detemir, a long-acting human insulin analog, on the survival rate of the pups. As expected, insulin detemir prolonged the survival rate and decreased the body weight gain in Gck Ϫ/Ϫ mice and reduced the blood glucose levels in all the genotypes (Supplemental Fig. 1 , A-C, published on The Endocrine Society's Journals Online web site at http://endo.endojournals.org). These results indicated that liraglutide was unable to compensate for the early lethality caused by the profound insulin depletion in the Gck Ϫ/Ϫ mice.
Liraglutide failed to prolong the survival of Gck
Liraglutide did not affect GSIS in Gck ؊/؊ neonatal islets
We first measured the casual serum insulin levels at P2 or P3 in WT, Gck ϩ/Ϫ , and Gck Ϫ/Ϫ pups treated with twice daily injections of either vehicle or liraglutide, as described above. We previously reported that basal insulin secretion was preserved in Gck Ϫ/Ϫ pups (22) . Consistent with this finding, the insulin levels were massively decreased, but not abolished, in these pups under casual nonfasting conditions (Fig. 4, A and B) . Liraglutide failed to compensate for the striking reduction in the serum insulin levels at both P2 and P3 in Gck Ϫ/Ϫ mice (Fig. 4, A and B) .
We next examined GSIS by islets isolated from WT, Gck ϩ/Ϫ , and Gck Ϫ/Ϫ pups at 3 d after birth (P3) in the presence or absence of liraglutide. As shown in Fig. 4C, the   FIG. 3 . Liraglutide did not prolong survival but reduced blood glucose levels in Gck Ϫ/Ϫ mice. Liraglutide or the vehicle was injected twice daily in WT (n ϭ 22 and 9), Gck ϩ/Ϫ (n ϭ 40 and 19), and Gck Ϫ/Ϫ (n ϭ 36 and 11) neonates, as described in Materials and Methods. A, Survival rate. B, Body weight changes. C, Plasma glucose levels. n.s., Not significant. *, P Ͻ 0.05; **, P Ͻ 0.01 vs. vehicle controls. Endocrinology, July 2012, 153(7):3066 -3075 endo.endojournals.org
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Gck Ϫ/Ϫ islets exhibited impaired insulin secretion at both low and high glucose concentrations, and their responses to glucose were diminished. Although insulin secretion at a glucose concentration of 22.2 mM showed a mild increment in the presence of liraglutide in islets from P3 WT and Gck ϩ/Ϫ mice, liraglutide had no effect on insulin secretion from Gck Ϫ/Ϫ islets (Fig. 4C) . About 50 -70% of the insulin secretion in the presence of potassium chloride was detected in P3 Gck Ϫ/Ϫ islets, compared with P3 WT and Gck ϩ/Ϫ islets (data not shown).
These results implied that glucokinase plays a critical role in liraglutide-induced insulin secretion from ␤-cells.
Elevations of plasma ALT, FFA, and TG were transiently prevented by liraglutide in Gck
؊/؊ mice A previous report demonstrated that both TChol and TG levels were elevated in neonatal systemic glucokinasedeficient mice, and glucokinase expression in ␤-cells restored these levels (21) . We determined the plasma ALT, FFA, TChol, and TG levels at P0 -P5 in WT, Gck ϩ/Ϫ , and Gck Ϫ/Ϫ pups. Gck Ϫ/Ϫ mice exhibited significant elevations in ALT, FFA, and TG until P2 (Supplemental Fig. 2 ). We next evaluated the effects of intermediate-acting human insulin (NPH) or liraglutide on the lipid profiles of these mice. NPH prevented the elevation in ALT, and liraglutide averted the increases in the ALT, FFA, and TG levels at P2 (Fig. 5A ), but not at P4 (Fig.  5B) , in Gck Ϫ/Ϫ mice. Liraglutide also reduced the plasma levels of FFA, TChol, and TG in both WT and Gck ϩ/Ϫ mice at P15 (Supplemental Fig. 3 ). In adult mice, glucokinase haploinsufficiency in the ␤-cells did not affect the plasma ALT level or the lipid profiles (Supplemental Fig. 4 ).
Liraglutide transiently protected against hepatic steatosis in Gck
؊/؊ mice Systemic glucokinase-deficient mice exhibited a significant reduction in liver glycogen stores and microvesicular steatosis, with an increase in vacuolization and lipid accumulation (21) . We examined the liver TG content and the liver glycogen content in WT, Gck ϩ/Ϫ , and Gck Ϫ/Ϫ pups. Gck Ϫ/Ϫ mice manifested a significant increase in liver TG and a decrease in liver glycogen at P2 (Fig. 6 , A and E, and Supplemental Fig. 5 ). Gross observation and histological analysis revealed fatty changes in the liver and steatosis with vacuolization in Gck Ϫ/Ϫ mice at P2 (Fig. 6 , B and C). In agreement with the transient amelioration of the increases in ALT, FFA, and TG induced by liraglutide in Gck Ϫ/Ϫ mice, liraglutide restored the increase in liver TG and the decrease in liver glycogen at P2 (Fig. 6A) , but not at P4 (Fig. 6E) , in Gck Ϫ/Ϫ mice. Liver steatosis was also improved by liraglutide at P2 in Gck Ϫ/Ϫ mice (Fig. 6 , B and C). Thus, liraglutide improved circulating lipids and hepatic steatosis in a ␤-cell glucokinase-independent fashion. Because liver glucokinase plays a key role in glycogen synthesis, we assessed the expression of glucokinase in the liver. P2Gck Ϫ/Ϫ mice exhibited a reduced expression of glucokinase in the liver, and liraglutide restored the expression level (Fig. 6D) . The amelioration of the histological changes and the glucokinase expression level in the liver by liraglutide also disappeared at P4 in Gck Ϫ/Ϫ mice (data not shown).
Liraglutide delayed ␤-cell loss in Gck ؊/؊ mice
We next investigated the histological analysis of endocrine pancreas in WT, Gck ϩ/Ϫ , and Gck Ϫ/Ϫ pups. Although all genotypes exhibited similar islet morphologies at P2 (Fig.  7, A and B) , a decrease in the ␤-cell mass and the ␤-cell ratio in the islet cells were observed in P4 Gck Ϫ/Ϫ mice, compared with WT and Gck ϩ/Ϫ mice (Fig. 7, C and D) . Liraglutide and NPH increased the ␤-cell mass and the ␤-cell ratio in islet cells in P4 Gck Ϫ/Ϫ mice (Fig. 7, C and D) . 
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Discussion
Glucokinase plays a central role as a glucose sensor in insulin-producing pancreatic islet ␤-cells and regulates GSIS (25, 26) . ␤ Cell-specific glucokinase-deficient (Gck Ϫ/Ϫ ) mice suffer from lethal hyperglycemia as a result of the lack of insulin secretion (22) . In this study, we investigated the effects of liraglutide on ␤-cell-specific glucokinase-deficient Gck Ϫ/Ϫ neonatal mice.
Insulin detemir, but not liraglutide, prolonged the survival of Gck Ϫ/Ϫ neonatal mice. However, liraglutide decreased the blood glucose levels in Gck Ϫ/Ϫ pups and prevented body weight gain in all genotypes. Furthermore, a single administration of liraglutide reduced the blood glucose levels in an insulin concentration-independent manner in both WT and Gck ϩ/Ϫ mice in the presence or absence of Atr and CS. These data suggest that the glucoselowering effect of liraglutide is mediated, at least in part, by extrapancreatic effects (e.g. gastrointestinal motility), and liraglutide failed to compensate for the severe impairment of insulin secretion in Gck Ϫ/Ϫ neonatal mice. It is possible that the attainment of blood glucose levels by liraglutide is insufficient to affect survivability in Gck Ϫ/Ϫ pups, and more intense treatments may be required to enhance survivorship. We demonstrated that liraglutide had no effects on insulin secretion in islets from Gck Ϫ/Ϫ neonatal mice. This result suggested that glucokinase is required for liraglutide action in insulin secretion from ␤-cells. In mice deficient in Kir6.2, an ATP-sensitive K ϩ channel, pretreatment with GLP-1 potentiated insulin secretion and prevented an elevation in the blood glucose level after a GTT (27) , whereas niflumic acid-sensitive ion channels are reportedly involved in the induction of GSIS by cAMP elevation after treatment with GLP-1 (28) . Therefore, glucokinase may contribute to pathways other than Kir6.2-mediated depolarization in liraglutide-induced insulin secretion. The assessment of cAMP levels before and after treatment with liraglutide in Gck Ϫ/Ϫ islets is needed to clarify the mechanisms that are involved. In human trials, liraglutide has been shown to induce significant reductions in T-Chol, low-density lipoprotein-cholesterol, and TG (6, 7, 9, 11) . Liraglutide also lowered the TG levels in type 2 diabetes rats (17) . We demonstrated the protective effects of liraglutide on elevations in ALT, FFA, and TG, and liraglutide improved hepatic steatosis in Gck Ϫ/Ϫ mice.
However, the significance of aspartate aminotransferase (AAT or AST), ALT, or AAT/ALT ratio in fatty liver of neonatal mice remains unclear. Measurement of AAT may contribute to unravel the complexity of this mechanism of action in these neonates. In previous studies, GLP1R-mediated signals ameliorated fatty liver (29, 30) , and DPP-4 inhibition protected against steatosis in a glucose-independent manner (4) . Reductions in body weight and energy intake resulting from liraglutide administration have been previously reported (31, 32) . The reduction in body weight gain observed in this study may have contributed to the improvements in the serum lipid parameters and the liver steatosis. One of the limitations of this study was its lack of weight-matched control groups to assess the influence of body weight changes on metabolic differences. In human hepatocytes, the expressions of GLP1R and GLP1R internalization by GLP-1 or exendin-4 have been reported (33) . Additionally, GLP-1 reportedly suppresses hepatic lipogenesis via the activation of the AMP-activated protein kinase pathway in rats (34) , raising the possibility that the prevention of liver steatosis by liraglutide was due to a glucokinase-independent direct action of GLP-1 on the liver. Liraglutide may be beneficial for the treatment of fatty liver even in patients in whom treatment with liraglutide does not lead to glycemic control. Because glucokinase expression in the liver is dependent on insulin, hepatic glucokinase expression was diminished in Gck Ϫ/Ϫ mice, regardless of the intact regulation of gene expression in the liver. Our data, however, indicated that the restoration of glucokinase expression in the liver by liraglutide is not induced by the elevation of serum insulin levels. Furthermore, a single administration of liraglutide by ip injection did not affect glucokinase expression in the liver, although a single administration of insulin significantly increased glucokinase expression (data not shown). Sterol regulatory element binding protein-1c, peroxisome proliferator-activated receptor-␥, liver X receptor-␣, small heterodimer partner, and PPAR␥ coactivator-1␣ are also involved in the regulation of glucokinase gene transcription in the liver (35, 36) . However, glucokinase gene expression induced by hormones other than insulin has been less well characterized. The reduction of serum glucagon levels by liraglutide may have contributed to the suppression of cAMP elevation in hepatocytes, resulting in an increase in glucokinase expression. Because the amelioration of glucokinase expression in the liver by liraglutide was also transient, glucokinase expression might have been regulated by the serum FFA and TG levels through genes controlling lipid metabolism in the liver. Further studyisrequiredtounravelthecomplexinteractionsinvolvedin the regulation of glucokinase expression in the liver.
Liraglutide also protected against ␤-cell loss without increasing insulin secretion in Gck Ϫ/Ϫ mice. Numerous reports have suggested that GLP1R activation has protective effects against ␤-cell damage (37). Our results suggest that liraglutide may also protect ␤-cells in the absence of glucokinase or irrespective of insulin secretion. The reduction in serum lipid levels may contribute to the avoidance of lipotoxicity in ␤-cells. In summary, we demonstrated that ␤-cell glucokinase is required for liraglutide-induced increments in insulin secre- tion. However, the serum lipid parameters, liver steatosis, and ␤-cell loss were improved by liraglutide in a glucokinaseand insulin-independent manner. Because GLP-1 is involved in many biological activities in the brain, endothelial cells, peripheral nerves, and blood cells, GLP1R activation may have multiple pleiotropic effects. The results of the current study suggest a novel therapeutic potential of liraglutide for noninsulinotropic effects in diabetic patients, but further research is needed to clarify the mechanisms that are involved.
